Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lercanidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | MTOR | P42345 | 2/20 | 0.98 |
| ▸ | RAB9A | P51151 | 2/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | CNR1 | P21554 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lercanidipine SCHEMBL29349606 | 1.00 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL8630225 | 1.00 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL9901189 | 0.99 | ADORA3 (0.97) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL2964657 | 0.99 | ADORA3 (0.97) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL2964655 | 0.99 | ADORA3 (0.97) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL9901187 | 0.99 | ADORA3 (0.97) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL9957683 | 0.99 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL8415026 | 0.99 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL25268 | 0.99 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL25269 | 0.99 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925616-B | Green synthesis method of lercanidipine hydrochloride | 安徽宏业药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| EP-3965759-B1 | A TABLET FORMULATION COMPRISING LERCANIDIPINE AND ENALAPRIL | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2025-02-12 | — | — | EP | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| CN-115671066-B | Lercanidipine hydrochloride tablet and preparation method thereof | 安徽宏业药业有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-117945985-A | Preparation method of lercanidipine hydrochloride | 福安药业集团重庆博圣制药有限公司 | 2024-04-30 | — | — | CN | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2023241402-A1 | PREDICTIVE MODEL FOR ABSORPTION RATE CONSTANT OF DRUG, DEVICE, AND STORAGE MEDIUM | 湖南慧泽生物医药科技有限公司 | 2023-12-21 | — | — | WO | claimed |
| CN-114822876-B | Predictive model, device and storage medium for drug absorption rate constant | 湖南慧泽生物医药科技有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-115590833-B | Lercanidipine hydrochloride tablet composition with high dissolution stability and preparation method thereof | 浙江和沐康医药科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115925616-A | Green synthesis method of lercanidipine hydrochloride | 安徽宏业药业有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| EP-1432683-A1 | NOVEL CRYSTALLINE POLYMORPHIC FORMS OF LERCANIDIPINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | Recordati Ireland Limited (IE) | 2004-06-30 | — | — | EP | claimed |
| EP-1423367-A1 | SOLVATES OF LERCANIDIPINE HYDROCHLORIDE AND NEW CRYSTALLINE FORMS OF LERCANIDIPINE HYDROCHLORIDE | Recordati Ireland Limited (IE) | 2004-06-02 | — | — | EP | claimed |
| US-20030083355-A1 | Novel crude and crystalline forms of lercanidipine hydrochloride | RECORDATI IRELAND LIMITED | 2003-05-01 | — | — | US | claimed |
| US-20030069285-A1 | Novel solvate and crystalline forms of lercanidipine hydrochloride | RECORDATI IRELAND LIMITED | 2003-04-10 | — | — | US | claimed |
| WO-2003014084-A1 | NOVEL CRYSTALLINE POLYMORPHIC FORMS OF LERCANIDIPINE HYDROCHLORIDE AND PROCESS FOR THEIR PREPARATION | RECORDATI IRELAND LIMITED (IE) | 2003-02-20 | — | — | WO | claimed |
| WO-2003014085-A1 | SOLVATES OF LERCANIDIPINE HYDROCHLORIDE AND NEW CRYSTALLINE FORMS OF LERCANIDIPINE HYDROCHLORIDE | RECORDATI IRELAND LIMITED (IE) | 2003-02-20 | — | — | WO | claimed |
| US-5912351-A | 2,N-DIMETHYL-N-(3,3-DIPHENYLPROPYL)-1-AMINO-2-PROPANAL IN AN APROTIC SOLVENT REACTED WITH 2,6-DIMETHYL-5-METHOXYCARBONYL-4-(3-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3 -CARBOXYLIC ACID; RECRYSTALLIZING LERCANIDIPINE CHLORIDE IN A SOLVENT MIXTURE | RECORDATI, S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-06-15 | — | — | US | claimed |
| WO-1990006123-A1 | THERAPEUTIC USE OF CALCIUM ENTRY BLOCKERS IN RETINAL OR OPTIC NERVE DYSFUNCTION | HOUSTON BIOTECHNOLOGY INCORPORATED (US) | 1990-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | CACNA1C 2207/4885ADORA3 25/4885ADRA1A 223/4885 |
| US-20030069285-A1 | Novel solvate and crystalline forms of lercanidipine hydrochloride | REN, ACE, ADRB3 | CACNA1C 14/4885ADORA3 1175/4885ADRA1A 219/4885 |
| US-20030083355-A1 | Novel crude and crystalline forms of lercanidipine hydrochloride | REN, ACE, AGTR2 | CACNA1C 15/4885ADORA3 1993/4885ADRA1A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.